RE: Nuclocapsid test3 Nov 2021 21:24
This is an interesting study. A good read.
Spike vs nucleocapsid SARS-CoV-2 antigen detection: application in nasopharyngeal swab specimens
https://link.springer.com/article/10.1007/s00216-021-03298-4#ref-CR39
Key points:
“Most of the FDA-approved commercial antigen kits (12 out of 13) target the nucleocapsid (NC). This protein, enclosed within the viral lipid membrane, is one of four structural proteins encoded by the SARS-CoV-2 positive-sense RNA viral genome. On November 3, 2020, the CDC issued a lab alert, expressing concerns regarding a potential for false positive results when implementing antigen tests for rapid detection of COVID-19, especially in the community [6]. A similar warning was issued by the FDA [7]. While this might be an inherent limitation of antibody-based tests, it could possibly be mitigated by targeting a different antigen. One such potential target is the spike protein (S).”
“The nucleocapsid, as well as open reading frames 3a and 8, is implicated as having roles in virulence, transmission, and pathogenicity [38] and is therefore as likely to undergo mutations as the spike protein despite not being presented on the virus surface. We therefore propose that for SARS-CoV-2 detection, both antigens will be used simultaneously or consecutively as was also suggested by others [39]. The combination of both antigens on the same device might strengthen the reliability of the observed result.”